Peripheral neuropathy in type 2 diabetes mellitus in Isfahan, Iran: prevalence and risk factors

Janghorbani, Mohsen; Rezvanian, Hassan; Kachooei, Ali; Ghorbani, Abbas; Chitsaz, Ahmad; Izadi, F Farzad; Amini, Masoud

doi:10.1111/j.1600-0404.2006.00716.x

Cited by 61 publications

(40 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It is reported that the advancing age increases the incidence of neuropathy. The average duration of diabetes in our study was 10 years which is not very long yet correlates well with previous reports [16,17]. Prolonged exposure of peripheral nerves to hyperglycemia in long standing diabetics predisposes them to development of neuropathy.…”

Section: Discussionsupporting

confidence: 91%

A study of the use of carbamazepine, pregabalin and alpha lipoic acid in patients of diabetic neuropathy

Patel¹,

Mishra²,

Patel

et al. 2014

J Diabetes Metab Disord

View full text Add to dashboard Cite

BackgroundDiabetic peripheral neuropathy (DPN) is a common, symptomatic, long-term complication of diabetes mellitus. Many of the agents used to treat DN have not been compared with each other. This study was, therefore, undertaken to compare the efficacy and safety of carbamazepine, pregabalin and alpha-lipoic acid in diabetic neuropathy patients.MethodsThis was a prospective, observational study. The patients were categorized into three groups, Group I included those patients who were prescribed carbamazepine while group II included those on pregabalin and group III patients received alpha-lipoic acid. Each patient was followed up at every month for total duration of 6 months. Demographic details, presenting symptoms, history of diabetes, laboratory values pertaining to diabetes (Fasting blood sugar, Post prandial blood sugar and HbA1c) were recorded. Intensity of pain, using a visual analogue scale (VAS), diabetic neuropathy symptom (DNS) score and diabetic neuropathy examination (DNE) score were assessed at baseline and then at each monthly follow-up. Nerve conduction velocity (NCV) was also measured at baseline and then at the end of 3 and 6 months.ResultsA total of 101 patients were enrolled out of them 96 completed the study. Regarding VAS, the number of patients having pain was reduced substantially however, the speed and the quantum of this reduction were best in group II (pregabalin). Regarding DNS, also group II showed the best response in terms of number of patients as well as the speed of improvement. The results also imply that the relief from diabetic neuropathy (as per DNE score) is superior with pregabalin administration. However, no improvement in NCV was evident in any group.ConclusionResults of this study suggest that treatment with pregabalin gives faster and better improvement in diabetic neuropathy.

show abstract

Section: Discussionsupporting

confidence: 91%

A study of the use of carbamazepine, pregabalin and alpha lipoic acid in patients of diabetic neuropathy

Patel¹,

Mishra²,

Patel

et al. 2014

J Diabetes Metab Disord

View full text Add to dashboard Cite

show abstract

“…In the present study, one hundred patients presented with DPN were included in the study. The result of the study showed that, the onset of DPN was early among female patients than males without statistically significant difference that agree with 17,18,19,20 . Also no significant difference development of DPN and age at onset of DM that agree with 21 .…”

Section: Discussion:-supporting

confidence: 74%

Risk Factors for Early Development of Polyneuropathy Among Type Ii Diabetic Patients.

HM¹,

HashemA²,

Mostafa³

2017

IJAR

View full text Add to dashboard Cite

“…In the present study, one hundred patients presented with DPN were included in the study. The result of the study showed that, the onset of DPN was early among female patients than males without statistically significant difference that agree with 17,18,19,20 . No significant correlation between development of DPN and age at onset of DM that agrees with 21 .…”

Section: Discussion:-supporting

confidence: 74%

Risk Factors for Early Development of Polyneuropathy Among Type Ii Diabetic Patients.

MahfouzH¹,

HashemA²,

Mostafa³

2017

IJAR

View full text Add to dashboard Cite

Peripheral neuropathy in type 2 diabetes mellitus in Isfahan, Iran: prevalence and risk factors

Abstract: Peripheral neuropathy is a common complication in this population of Iranian type 2 diabetic patients. It increases with age, duration of diabetes and proteinuria.

Cited by 61 publications

References 34 publications

A study of the use of carbamazepine, pregabalin and alpha lipoic acid in patients of diabetic neuropathy

A study of the use of carbamazepine, pregabalin and alpha lipoic acid in patients of diabetic neuropathy

Risk Factors for Early Development of Polyneuropathy Among Type Ii Diabetic Patients.

Risk Factors for Early Development of Polyneuropathy Among Type Ii Diabetic Patients.

Contact Info

Product

Resources

About